Article Details

Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML - OncLive

Retrieved on: 2024-09-30 23:48:59

Tags for this article:

Click the tags to see associated articles and topics

Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML - OncLive. View article details on hiswai:

Excerpt

Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo